ModerateFat-soluble vitamin E×Estrogens – natural and semisynthetic
Updated · Methodology
Mechanism
Vitamin E is metabolised in the liver to tocopheronic acid glucuronides and is excreted mainly in the bile (Auxina E SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The liver and other tissues convert estradiol to estrone, estriol and their sulfate and glucuronide conjugates, partly through CYP3A4 (Progynova SmPC, AEMPS; estradiol label, US Food and Drug Administration, FDA). The documents say nothing about either substance changing the levels of the other. The risk of the combination concerns thrombosis. Hormone replacement therapy is associated with a 1.3- to 3-fold higher risk of venous thromboembolism, more likely in the first year, and estrogen use is one of the recognised risk factors (Progynova SmPC, AEMPS). In predisposed people taking high doses of vitamin E, the risk of thrombophlebitis is higher, including in those who take estrogens. Estrogens taken with vitamin E may increase the risk of thrombosis (Auxina E SmPC, AEMPS).
Symptoms
The documents describe no cases linked to this combination. The vitamin E SmPC warns about thrombophlebitis, seen mainly at doses of 400 IU a day or more and more often in people with conditions that predispose to small-vessel disease (Auxina E SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The estradiol SmPC lists the signs of venous thrombosis and embolism: painful swelling of a leg, sudden chest pain and shortness of breath (Progynova SmPC, AEMPS). Long-term use of high doses of vitamin E on its own rarely causes diarrhoea, nausea, flatulence, abdominal cramps, bleeding gums, weakness, dizziness, headache and blurred vision (Auxina E SmPC, AEMPS).
Management
No document names estradiol. The Spanish vitamin E SmPC refers to estrogens as a class and warns that, taken with vitamin E, they may increase the risk of thrombosis. In predisposed people taking high doses of vitamin E, the risk of thrombophlebitis is higher, including in those who take estrogens (Auxina E SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The documents give no specific action for this combination. Before estradiol is started, a full personal and family medical history is taken, and risk factors for venous thromboembolism are assessed and managed (Progynova SmPC, AEMPS; estradiol label, US Food and Drug Administration, FDA). When several risk factors are present, bear in mind that the risk of thrombosis may rise by more than the sum of the individual factors (Progynova SmPC, AEMPS). Warn the woman about the signs of thrombosis: painful swelling of a leg, sudden chest pain and shortness of breath. If thrombosis develops or is suspected, stop estradiol at once (Progynova SmPC, AEMPS; estradiol label, FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Alfa-tocoferol (nº registro 62277), sección 4.5 (2026)– AEMPS, CIMA, nº registro 62277, revisión 10/2026, sección 4.5
- AEMPS: Ficha técnica: Estradiol, Progynova 1 mg (nº registro 47814), sección 4.4 (2026)– AEMPS, CIMA, nº registro 47814 (Progynova 1 mg comprimidos recubiertos, Bayer Hispania), revisión 02/2026, secciones 4.1, 4.4 y 4.5
- FDA: Estradiol tablets, Teva (estradiol) prescribing information (2024)– FDA, DailyMed setid c4936878-1643-4e7f-9b0d-e4957935aef2 (Teva Pharmaceuticals USA), revisión 02/2024 (versión 16), CLINICAL PHARMACOLOGY (Drug Interactions), PRECAUTIONS (Fluid retention, Exacerbation of other conditions)